Guobin Weng
Impact in
-
- Cancer Immunotherapy and Biomarkers
- Cytokine Signaling Pathways and Interactions
-
- Prostate Cancer Treatment and Research
- Renal cell carcinoma treatment
Papers in
-
- Renal cell carcinoma treatment 10
- Ferroptosis and cancer prognosis 3
- Prostate Cancer Treatment and Research 2
- Kidney Stones and Urolithiasis Treatments 2
- Prostate Cancer Diagnosis and Treatment 2
-
- Epigenetics and DNA Methylation 2
- Cell death mechanisms and regulation 2
- Co-authors
- Lijun Xu (2 shared papers)Yuhchyau Chen (2 shared papers)Soo Ok Lee (3 shared papers)Peter C. Keng (3 shared papers)Mingjing Shen (1 shared paper)Ying Tsai (1 shared paper)Dongrong Yang (1 shared paper)Shuaishuai Huang (9 shared papers)
- Journals
- Frontiers in Oncology (2 papers)Acta Pharmaceutica (2 papers)Scientific Reports (2 papers)BMC Urology (2 papers)BMC Cancer (1 paper)
- Partner nations
- ChinaUnited States
In The Last Decade
Guobin Weng
31 papers receiving 354 citations
Peers
Comparison fields: 5 of 53
- Oncology 70
- Pulmonary and Respiratory Medicine 85
- Health Informatics 6
- Immunology 37
- Cancer Research 24
Countries citing papers authored by Guobin Weng
This map shows the geographic impact of Guobin Weng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guobin Weng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guobin Weng more than expected).
Fields of papers citing papers by Guobin Weng
This network shows the impact of papers produced by Guobin Weng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guobin Weng. The network helps show where Guobin Weng may publish in the future.
Co-authors
The 25 scholars most cited alongside Guobin Weng, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 33 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2017 | 117 | |
| 2 | 2011 | 39 | |
| 3 | 2014 | 34 | |
| 4 | 2019 | 20 | |
| 5 | 2022 | 19 | |
| 6 | 2016 | 15 | |
| 7 | 2021 | 14 | |
| 8 | 2020 | 11 | |
| 9 | 2017 | 10 | |
| 10 | 2018 | 10 | |
| 11 | 2017 | 9 | |
| 12 | 2018 | 9 | |
| 13 | 2021 | 6 | |
| 14 | 2023 | 6 | |
| 15 | 2019 | 5 | |
| 16 | 2023 | 5 | |
| 17 | Prostate stem cell antigen variation rs2294008 associated with the risk of bladder cancer. | 2015 | 4 |
| 18 | 2023 | 4 | |
| 19 | 2019 | 3 | |
| 20 | 2022 | 3 |
About Guobin Weng
Guobin Weng is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology, Oncology, Rheumatology and Transplantation, having authored 33 papers that have together received 361 indexed citations. Recurring topics across this work include Renal cell carcinoma treatment (10 papers), Ferroptosis and cancer prognosis (3 papers), Prostate Cancer Treatment and Research (2 papers), Epigenetics and DNA Methylation (2 papers), Kidney Stones and Urolithiasis Treatments (2 papers), Cell death mechanisms and regulation (2 papers), Prostate Cancer Diagnosis and Treatment (2 papers) and Microtubule and mitosis dynamics (1 paper). The work is most often cited by research in Oncology (70 citations), Pulmonary and Respiratory Medicine (85 citations), Health Informatics (6 citations), Immunology (37 citations) and Cancer Research (24 citations). Guobin Weng has collaborated with scholars based in China and United States. Frequent co-authors include Lijun Xu, Yuhchyau Chen, Soo Ok Lee, Peter C. Keng, Mingjing Shen, Ying Tsai, Dongrong Yang, Shuaishuai Huang, Jianjian Zheng and Ling Wu. Their work appears in journals such as Frontiers in Oncology, Acta Pharmaceutica, Scientific Reports, BMC Urology and BMC Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.